GlobeNewswire

Novavax Reports First Quarter 2019 Financial Results

Del

            Company to Host Conference Call Today at 4:30 p.m. ET

GAITHERSBURG, Md., May 02, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq: NVAX) today announced its financial results and operational highlights for the first quarter ended March 31, 2019.

First Quarter 2019 and Subsequent Operational Highlights

ResVax ™ Program

  • In February 2019, Novavax announced top-line data from the Prepare™ trial, which was designed to determine the efficacy of ResVax™ against medically significant respiratory syncytial virus (RSV)-positive lower respiratory tract infection (LRTI) in infants. ResVax is the first RSV vaccine to demonstrate efficacy in infants.
     
  • In April 2019, Novavax presented additional results at the World Vaccine Congress in Washington, D.C. from the Prepare trial of ResVax. Although the Prepare trial results did not meet the pre-specified primary efficacy endpoint, it demonstrated efficacy against RSV LRTI hospitalizations, a pre-specified secondary endpoint. RSV LRTI hospitalization is not only an important indication of the severity of RSV disease in infants, it also reflects a significant economic burden to global health systems.

NanoFlu™ Program

  • In January 2019, Novavax announced positive top-line results of its Phase 2 clinical trial of NanoFlu comparing various quadrivalent formulations, with or without Novavax’ Matrix-M™ adjuvant, with two U.S.-licensed influenza vaccines in older adults. These results show that NanoFlu with Matrix-M generated enhanced immune responses compared to the unadjuvanted formulation, and importantly, showed superior hemagglutination inhibition antibody (HAI) responses against wild-type A(H3N2) viruses, including drifted strains, when compared to Fluzone® High-Dose, the leading flu vaccine in older adults.

Key Upcoming Events

  • Meet with the FDA, European regulatory agencies, and potentially other national regulatory agencies during the second and third quarters, to assess opportunities for submission of marketing applications for ResVax.
  • Reach agreement with the FDA during the third quarter of 2019 on a proposed Phase 3 clinical trial design for NanoFlu utilizing accelerated approval criteria for licensure.
  • Present ResVax Phase 3 clinical trial data at the 37th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) on May 7, 2019.

Financial Results for the First Quarter Ended March 31, 2019

Novavax reported a net loss of $43.2 million, or $0.11 per share, for the first quarter of 2019, compared to a net loss of $46.4 million, or $0.14 per share, for the first quarter of 2018.

Novavax revenue in the first quarter of 2019 was $4.0 million, compared to $9.7 million in the same period in 2018. This 59% decrease was driven by the completion of enrollment of the Prepare trial in the second quarter of 2018.

Research and development expenses decreased 20% to $35.5 million in the first quarter of 2019, compared to $44.5 million for the same period in 2018. This decrease was primarily due to decreased development activities, including lower clinical trial costs, of ResVax.

General and administrative expenses were flat at $8.7 million in the first quarter of 2019, compared to the same period of 2018.

Interest income (expense), net was ($3.0) million in the first quarter of 2019, compared to ($2.9) million for the same period of 2018.

As of March 31, 2019, Novavax had $108.7 million in cash, cash equivalents, marketable securities and restricted cash, compared to $103.9 million as of December 31, 2018. Net cash used in operating activities for the first quarter of 2019 was $50.6 million, compared to $66.1 million for same period in 2018.

Conference Call

Novavax will host its quarterly conference call today at 4:30 p.m. ET. The dial-in numbers for the conference call are (877) 212-6076 (Domestic) or (707) 287-9331 (International), passcode 5394082. A replay of the conference call will be available starting at 7:30 p.m. ET on May 2, 2019 until 7:30 p.m. ET on May 9, 2019. To access the replay by telephone, dial (855) 859-2056 (Domestic) or (404) 537-3406 (International) and use passcode 5394082.

A webcast of the conference call can also be accessed via a link on the home page of the Novavax website (novavax.com) or through the “Investor Info”/“Events” tab on the Novavax website. A replay of the webcast will be available on the Novavax website until August 2, 2019.

About RSV in Infants

Globally, RSV (respiratory syncytial virus) is the leading viral cause of severe lower respiratory tract disease in infants and young children. It is the second leading cause of death in children under one year of age. Estimated annual hospitalizations of 1.4 million and an estimated 27,300 in-hospital deaths were due to RSV acute lower respiratory infection in children under six months of age. RSV results in a total global economic burden of $6.2 billion annually.

In the U.S., RSV is the leading cause of hospitalization of infants. Estimated annual hospitalizations are up to 76,000. While RSV can impact all infants, babies under six months of age are among those at highest risk, as approximately 77% of all first-year RSV infections occur before six months. In the U.S., the total economic burden is $2.7 billion annually.

About ResVax™

ResVax is an RSV fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant. It is being developed to protect infants from RSV disease via maternal immunization, which may offer the best method of protection from RSV disease in infants through the first months of life. In February 2019, Novavax announced top-line data from Prepare™, a global Phase 3 clinical trial in 4,636 pregnant women, at least 3,000 of whom have received the vaccine, and their infants. Prepare is supported by an $89.1 million grant from the Bill & Melinda Gates Foundation (BMGF).

About Influenza

Influenza is a world-wide infectious disease that causes illness in humans with symptoms ranging from mild to life-threatening or even death. Serious illness occurs not only in susceptible populations such as infants, young children and older adults, but also in the general population largely because of infection by continuously evolving strains of influenza which can evade the existing protective antibodies in humans. An estimated one million deaths globally each year are attributed to influenza. Current estimates for seasonal influenza vaccine growth in the top seven markets (U.S., Japan, France, Germany, Italy, Spain and UK), show a potential increase from approximately $3.2 billion in 2012-13 season to $5.3 billion by the 2021-22 season.

About NanoFlu™ and Matrix M™

NanoFlu is a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine produced by Novavax in its SF9 insect cell baculovirus system. NanoFlu uses HA protein amino acid sequences that are the same as the recommended wild-type circulating virus HA sequences. NanoFlu contains Novavax’ patented saponin-based Matrix-M adjuvant, which is potent and well- stimulates both high quality and durable antibody responses as well as multifunctional CD4 and CD8 T-cell responses. In January 2019, Novavax announced positive top-line data from its Phase 2 clinical trial in older adults of quadrivalent formulations of NanoFlu in 1,375 healthy older adults across clinical sites in the U.S.

About Accelerated Approval

Accelerated approval may be granted for certain biological products that have been studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments. Such an approval will be based on adequate and well-controlled clinical trials establishing that the biological product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. For seasonal influenza vaccines, the hemagglutination inhibition (HAI) antibody response may be an acceptable surrogate marker of activity that is reasonably likely to predict clinical benefit. To be considered for accelerated approval, a biologics license application for a new seasonal influenza vaccine should include results from one or more well-controlled studies designed to meet immunogenicity endpoints and a commitment to conduct confirmatory post-marketing studies of clinical effectiveness in preventing influenza.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Its two priority programs are ResVax™, its RSV vaccine for infants via maternal immunization, and NanoFlu™, its quadrivalent influenza nanoparticle vaccine. Novavax’ proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2018, and Quarterly Report on Form 10-Q for the period ended March 31, 2019, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.


NOVAVAX, INC.  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
(in thousands, except per share information)

(unaudited)
 
                     
          Three Months Ended
          March 31
                2019       2018  
               
               
Revenue         $      3,982     $      9,653  
                   
Expenses:              
  Research and development           35,473       44,514  
  General and administrative           8,732       8,652  
    Total expenses           44,205       53,166  
Loss from operations           (40,223 )     (43,513 )
Interest income (expense), net           (2,983 )     (2,872 )
Other income (expense)           (12 )     33  
Net loss         $     (43,218 )   $     (46,352 )
                   
Basic and diluted net loss per share         $     (0.11 )   $     (0.14 )
Basic and diluted weighted average              
  number of common shares outstanding           408,843       336,972  

SELECTED CONSOLIDATED BALANCE SHEET DATA
(in thousands)

  March 31,
2019
  December 31,
2018
  (unaudited)    
       
Cash and cash equivalents 97,711     70,154  
Marketable securities 2,484     21,980  
Total restricted cash 8,488     11,805  
Total current assets 123,394     119,276  
Working capital 91,898     73,737  
Total assets 221,319     207,978  
Notes payable 319,543     319,187  
Total stockholders’ deficit (150,583 )   (167,935 )

Contacts:      

Investors
Novavax, Inc.
Erika Trahan
ir@novavax.com
240-268-2000

Westwicke
John Woolford
john.woolford@westwicke.com
443-213-0506

 

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Governance reform could see African economies benefit to tune of £23bn - PwC Global Economy Watch20.5.2019 12:00:00 CESTPressemelding

Continent-wide analysis of African economies demonstrates positive correlation between economic growth and rising governance indicators Ethiopia and Cote d’Ivoire demonstrate consistent annual average real per-capita growth of >5% since 2013 Particularly strong growth among East African economies (average 3% per capita), while Central Africa has struggled (fall by average 1.3%) Global analysis highlights slowdown in manufacturing sector linked to US-China trade war LONDON, May 20, 2019 (GLOBE NEWSWIRE) -- The latest edition of PwC’s bimonthly Global Economy Watch has found that African economies could receive a windfall of £23bn if each economy applied similar governance reforms equivalent to those made by Cote d’Ivoire since 2013. The continent-wide economic analysis modelled the performance of each country across six of the World Bank’s Worldwide Governance Indicators (2013-17), which covers aspects such as regulatory quality, rule of law and government effectiveness. The analysis ha

Levine Leichtman Capital Partners Promotes Monty Ismail to Senior Associate20.5.2019 11:00:00 CESTPressemelding

LOS ANGELES, May 20, 2019 (GLOBE NEWSWIRE) -- Levine Leichtman Capital Partners (“LLCP”), a Los Angeles-based private equity firm, is pleased to announce the promotion of Monty Ismail to Senior Associate. Mr. Ismail joined the London office of Levine Leichtman Capital Partners in 2018. Since that time, he has participated in several successful transactions, including the add-on acquisition of Globe Business Media Group for Law Business Research Ltd. and the recent acquisition of SK AeroSafety. As a dedicated member of the firm’s Structured Equity investment team, he will continue to monitor LLCP portfolio companies as well as be responsible for investment due diligence and analysis of new investment opportunities. “Monty has been an important member of the Levine Leichtman Capital Partners team. He has contributed significantly to the success of our London office and we are excited for his continued growth within the firm,” said Lauren Leichtman, LLCP’s co-founder. For more information

WindSim Names Donna Rennemo Chief Executive Officer20.5.2019 11:00:00 CESTPressemelding

TONSBERG, Norway and WESTLAKE VILLAGE, Calif., May 20, 2019 (GLOBE NEWSWIRE) -- WindSim AS, the leading provider and pioneer of CFD (Computational Fluid Dynamics) based Wind Farm Design Tools (WFDT) utilized for the design of wind farms both onshore and offshore, has today announced that its board of directors has appointed Donna Rennemo as president and chief executive officer. This leadership appointment is effective immediately and follow the Board of Directors in WindSim and John Olaf Rømma agreement to step down as the company’s CEO. “We are fortunate to have someone of Donna Rennemo’s caliber and experience to step up to lead WindSim,” said Dag Honningsvåg, WindSim Chairman of the Board. “We are at a critical moment and we need renewed leadership to successfully implement our strategy and take advantage of the market opportunities ahead. Rennemo is a technology visionary with a proven track record of execution. She is a strong communicator who is customer focused with deep leader

TransCanna Executes LOI To Acquire The Business and Assets of Premier Indoor Cultivator Lyfted Farms20.5.2019 09:05:00 CESTPressemelding

VANCOUVER, British Columbia, May 20, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – TransCanna Holdings Inc. (CSE:TCAN: XETR: TH8) (“TransCanna” or the “Company”) is pleased to announce the execution of a non-binding Letter Of Intent dated May 17, 2019 (the “LOI”) with Lyfted Farms, Inc. (“Lyfted”), of Modesto, California, to acquire the business and assets of Lyfted (the “Proposed Acquisition”). Lyfted Farms is a state licensed producer of high quality indoor grown cannabis. The three permanent state licenses that Lyfted owns are for cultivation (nursery), cultivation (grow), and distribution. “The Proposed Acquisition includes an exceptional brand, with a range of high-end flower, growing revenues, fifty exotic and unique genetic strains and a team that’s been a staple in the Modesto valley with over two decades of cultivating experience. In short, this is another example of an ideal acquisition candidate for TransCanna that offers SKU velocity, growing revenues and branded products that

Fortuna CEO purchases company shares17.5.2019 21:00:00 CESTPressemelding

VANCOUVER, British Columbia, May 17, 2019 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE: FSM) (TSX: FVI) reports that Jorge A. Ganoza, Chief Executive Officer of the Company, has increased his equity position in the Company by acquiring 170,000 common shares on the open market at an average price of US$2.59 per share. An insider report filing reflecting the share acquisition has been made on the SEDI website at www.sedi.ca. About Fortuna Silver Mines Inc. Fortuna is a growth oriented, precious metal producer with its primary assets being the Caylloma silver mine in southern Peru, the San Jose silver-gold mine in Mexico and the Lindero gold Project, currently under construction, in Argentina. The Company is selectively pursuing acquisition opportunities throughout the Americas and in select other areas. For more information, please visit its website at www.fortunasilver.com. ON BEHALF OF THE COMPANY Carlos Baca Investor Relations Manager Trading symbols: NYSE: FSM | TSX: FVI Inves

Oxford Immunotec Welcomes Updated CDC Recommendations for Tuberculosis Screening and Testing of Healthcare Personnel17.5.2019 15:25:00 CESTPressemelding

OXFORD, United Kingdom and MARLBOROUGH, Mass., May 17, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it welcomes the updated Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019, published by the U.S. Centers for Disease Control and Prevention (CDC)1. These guidelines increase the focus on eradicating tuberculosis (TB) disease in the United States through an individual risk-based approach to screening and treatment for Healthcare Personnel (HCP). Key highlights from the updated guidelines include: Recommendation for TB Screening and Individual Based TB Risk Assessment on Hire : continue baseline screening of all HCPs upon hire with the addition of an individual risk assessment Recommendation to Focus Serial Testing on Higher Risk Individuals: decision to perform TB testing afte